Shares in pharmaceutical company AstraZeneca rose by more than  on Monday after US giant Pfizer confirmed its interest in a takeover bid  The firm said it had contacted AstraZeneca over a multibillion pound bid for the UKbased drug maker If successful the deal would be the biggest ever takeover of a UK firm by a foreign company Pfizer said it approached AstraZeneca on Saturday after an initial offer in January worth bn was rebuffed AstraZeneca said the original offer significantly undervalued the firm which employs more than  staff However AstraZeneca said it was confident its strategy would create significant value for shareholders on its own The Board remains confident in the ongoing execution of AstraZenecas strategy as an independent company it added Pfizer said   that AstraZenecas refusal to engage meant it was currently considering its options AstraZeneca manufactures drugs in  countries focusing on treatments for diabetes cancer and asthma as well as antibiotics It reported bn in sales last year with bn in pretax profit In the UK it has eight sites and about  employees  Recently it posted a drop in first quarter profits  and laid off thousands of staff in an effort to reduce its costs to compensate for a fall in sales  due to patent losses on blockbuster medicines In April it posted a drop in first quarter profits after its earnings were by hit by patents expiring on some of its older medicines Pfizer said its initial offer in January was a combination of cash and shares worth  per AstraZeneca share worth bn in total At the time it represented a  premium to AstraZenecas share price although AstraZenecas share price has since increased and on Monday morning it jumped nearly  to p Pfizer said the deal was a highly compelling opportunity for AstraZenecas shareholders It said if the takeover went through the combined firm would have management in both the US and the UK but would list its shares on the New York Stock Exchange We have great respect for AstraZeneca and its proud heritage said Pfizer chairman and chief executive Ian Read  Pfizer said it would only make a firm offer if AstraZeneca directors voted unanimously in favour of the deal  The strategic business and financial rationale for a transaction is compelling it added Buying AstraZeneca would give Pfizer whose drugs include Viagra access to a number of cancer and diabetes drugs However Justin Urquhart Stewart head of corporate development at Seven Investment Management told the BBC the price Pfizer is offering was still too low to secure a deal Its too close to what it is priced at in the market he said Theyve tried to talk to the management and gain agreement but thats not happened so they are considering now going directly to the shareholders    Citi analyst Andrew Baum said he believed there was now a  chance that Pfizer would acquire AstraZeneca for at least around  a share Linda Yueh the BBCs chief business correspondent notes that AstraZeneca is a key UK firm in the area of research and development RD and also in exports AstraZenecas bn of drugs sold every year accounts for a whopping  of British goods exports she added  Pfizer has made other major acquisitions its most recent being the bn bn purchase of Wyeth in  However this would mark its biggest foreign acquisition It would also be the largest foreign takeover of a British firm beating some of the more recent deals which include However the BBCs business editor Kamal Ahmed warned Pfizers takeover approach could turn into a lengthy battle If AstraZeneca does not engage and it hasnt so far this bid could turn hostile he said Reacting to news of the bid Business Secretary Vince Cable said My priority is to ensure that the objectives of this governments life sciences industrial strategy are fulfilled This means ensuring there are highskilled jobs and long term investment in research and development in the UK  On the potential merger the CEO of Pfizer has made contact and informed me of his intentions and I have emphasised the importance of these points